2023年欧洲肿瘤内科学会（ESMO）年会将于10月20日-24日在西班牙马德里召开。ESMO大会涵盖基础研究、转化研究以及最新临床研究进展，将为临床实践、多学科讨论等提供广阔、卓越的学术平台。医脉通编辑特整理消化系统肿瘤重磅研究如下，以飨读者。

口头报告1 - 下消化道胃肠道肿瘤

Proffered Paper session 1 - Gastrointestinal tumours, lower digestive 

日期：2023年10月21日，星期六

时间：14:45 - 16:15

主席：Chiara Cremolini (Pisa, Italy) ,Rodrigo Dienstmann (Sao Paulo, Brazil)

地点：Sevilla Auditorium - Hall 9

01

摘要号：LBA25

标题：Neoadjuvant short-course radiotherapy followed by camrelizumab plus chemotherapy versus long-course chemoradiotherapy followed by chemotherapy in locally advanced rectal cancer: a randomized phase III trial (union )

报告人：林振宇（华中科技大学附属协和医院）

时间：14:45 - 14:55

02

摘要号：LBA26

标题：Neoadjuvant Chemotherapy with CAPOX versus Chemoradiation for Locally Advanced Rectal Cancer with Uninvolved Mesorectal Fascia (CONVERT): Final Results of a Phase III Trial

报告人：丁培荣（中山大学肿瘤防治中心）

时间：14:55 - 15:05

03

摘要号：549O

标题：Adagrasib With or Without Cetuximab in Patients With KRASG12C-Mutated Colorectal Cancer (CRC): Analysis of Tumor Biomarkers and Genomic Alterations

报告人：Meredith S. Pelster（Nashville, United States of America）

时间：15:25 - 15:35

04

摘要号：550O

标题：Safety and efficacy of D-1553 in combination with cetuximab in KRAS G12C mutated colorectal cancer (CRC): a phase II study

报告人：徐瑞华（中山大学肿瘤防治中心）

时间：15:35 - 15:45

口头报告2 - 下消化道胃肠道肿瘤

Proffered Paper session 2 - Gastrointestinal tumours, lower digestive 

日期：2023年10月23日，星期一

时间：08:30 - 10:00

主席：Clara Montagut Viladot (Barcelona, Spain), Dominik P. Modest (Berlin, Germany)

地点：Barcelona Auditorium - Hall 9

01

摘要号：LBA27

标题：First-line systemic treatment in patients with initially unresectable colorectal cancer liver metastases (CRLM): overall survival of the phase III CAIRO5 study of the Dutch Colorectal Cancer Group

报告人：Cornelis J. Punt（Utrecht, Netherlands）

时间：08:40 - 08:50

02

摘要号：LBA28

标题：The PEGASUS trial: post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients

报告人：Sara Lonardi（Padova, Italy）

时间：09:10 - 09:20

03

摘要号：LBA29

标题：Aspirin After Standard Adjuvant Therapy for Colorectal Cancers (ASCOLT) - An International, Phase III, Randomised, Placebo-controlled Trial

报告人：John W. Chia （Singapore, Singapore）

时间：09:20 - 09:30

04

摘要号：552O

标题：FOxTROT: results of embedded phase II evaluating the addition of panitumumab (pan) to neo-adjuvant FOLFOX for patients (pts) with KRAS-wt colon cancer (CC) with extended biomarker panel

报告人：Jenny Seligmann（Leeds, United Kingdom）

时间：08:30 - 08:40

迷你口头报告 - 下消化道胃肠道肿瘤

Mini oral session - Gastrointestinal tumours, lower digestive

日期：2023年10月22日，星期日

时间：14:45 - 16:20

主席：Gunnar Folprecht (Dresden, Germany), Raghav Sundar (Singapore, Singapore), Jeanne Tie (Melbourne, Australia)

地点：Burgos Auditorium - Hall 3

01

摘要号：LBA30

标题：Panitumumab (P) + FOLFIRINOX or mFOLFOX6 in unresectable metastatic colorectal cancer (mCRC) patients (pts) with RAS/BRAF wild-type (WT) tumor status from circulating DNA (cirDNA). First results of the randomised phase II PANIRINOX-UCGI28 study

报告人：Thibault Mazard（Montpellier, Cedex 5, France）

时间：14:45 - 14:50

02

摘要号：LBA31

标题：Neoadjuvant nivolumab plus relatlimab (anti-LAG3) in locally advanced MMR-deficient colon cancers: the NICHE-3 study

报告人：Yara L. Verschoor（Amsterdam, Netherlands）

时间：15:15 - 15:20

03

摘要号：LBA32

标题：Pembrolizumab versus chemotherapy in microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): 5-year follow-up of the randomized phase 3 KEYNOTE-177 study

报告人：Kai-Keen Shiu（London, United Kingdom）

时间：15:25 - 15:30

04

摘要号：554MO

标题：Cetuximab Plus FOLFOXIRI Versus Cetuximab Plus FOLFOX as conversion therapy in RAS Wild-type Patients with Initially Unresectable Colorectal Liver

报告人：陈功（中山大学肿瘤防治中心）

时间：14:50 - 14:55

05

摘要号：555MO

标题：Modified (m)-FOLFOXIRI plus cetuximab treatment and predictive clinical factors for RAS/BRAF wild-type and left-sided metastatic colorectal cancer (mCRC): the DEEPER trial (JACCRO CC-13)

报告人：Yu Sunakawa（Kawasaki, Japan）

时间：14:55 - 15:00

06

摘要号：556MO

标题：A phase II clinical trial of sintilimab plus chidamide combined with or without bevacizumab in patients with MSS/pMMR metastatic colorectal cancer

报告人：王峰（中山大学肿瘤防治中心）

时间：15:20 - 15:25

07

摘要号：558MO

标题：Circulating tumor (ct)DNA as a prognostic biomarker in patients (pts) with resected colorectal cancer (CRC): an updated 24 months (mos) disease free survival (DFS) analysis from GALAXY study (CIRCULATE-Japan)

报告人：Yoshiaki Nakamura（Kashiwa, Japan）

时间：15:50 - 15:55

口头报告1 - 上消化道胃肠道肿瘤

Proffered Paper session 1 - Gastrointestinal tumours, upper digestive

日期：2023年10月20日，星期五

时间：14:45 - 16:15

主席：Göran Jönsson (Lund, Sweden)

地点：Santander Auditorium - Hall 9

01

摘要号：LBA73

标题：Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): interim results of the global, Phase 3 MATTERHORN study

时间：14:10 - 14:20

02

摘要号：LBA74

标题：Pembrolizumab plus chemotherapy vs chemotherapy as neoadjuvant and adjuvant therapy in locally-advanced gastric and gastroesophageal junction cancer: The Phase 3 KEYNOTE-585 study

报告人：Kohei Shitara（Kashiwa, Japan）

时间：14:00 - 14:10

03

摘要号：1511O

标题：Pembrolizumab plus Trastuzumab and Chemotherapy for HER2+ Metastatic Gastric or Gastroesophageal Junction (mG/GEJ) Adenocarcinoma: Survival results from the Phase 3, Randomized, Double-blind, Placebo-controlled KEYNOTE-811 Study

报告人：Yelena Y. Janjigian（New York, United States of America）

时间：15:10 - 15:20

口头报告2 - 上消化道胃肠道肿瘤

Proffered Paper session 2 - Gastrointestinal tumours, upper digestive

日期：2023年10月22日，星期日

时间：10:15 - 11:45

地点：Barcelona Auditorium - Hall 9

01

摘要号：LBA76

标题：The primary results of an intergroup phase III randomized controlled trial comparing ramucirumab plus irinotecan with irinotecan in the third or later line treatment beyond progression after ramucirumab for advanced gastric cancer (RINDBeRG Trial).

报告人：Shigenori Kadowaki（Nagoya, Japan）

时间：11:05 - 11:15

02

摘要号：LBA83

标题：Neoadjuvant chemotherapy with FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy for borderline resectable and resectable pancreatic cancer (PREOPANC-2): a multicenter randomized controlled trial

报告人：Bas Groot Koerkamp（Rotterdam, Netherlands）

时间：10:25 - 10:35

03

摘要号：1616O

标题：Nab-paclitaxel plus gemcitabine versus modified FOLFIRINOX or S-IROX in metastatic or recurrent pancreatic cancer (JCOG1611, GENERATE): a multicenter, randomized, open-label, three-arm, phase 2/3 trial

报告人：Akihiro Ohba（Chuo-ku, Japan）

时间：10:15 - 10:25

迷你口头报告 - 上消化道胃肠道肿瘤

Mini oral session - Gastrointestinal tumours, upper digestive

日期：2023年10月21日，星期六

时间：16:30 - 18:10

主席：Lorenza Rimassa (Rozzano, Italy), Tania C. Fleitas (Valencia, Spain)

地点：Bilbao Auditorium - NCC

01

摘要号：LBA78

标题：Overall Survival of Perioperative or Postoperative Adjuvant Oxaliplatin with S-1 versus Adjuvant Oxaliplatin with Capecitabine in Locally Advanced Gastric or Gastro-Oesophageal Junction Adenocarcinoma Undergoing D2 Gastrectomy: An Updated Analysis of RESOLVE Trial

报告人：张小田（北京大学肿瘤医院）

时间：17:00 - 17:05

02

摘要号：LBA79

标题：GEMSTONE-303: prespecified progression-free survival (PFS) and overall survival (OS) final analyses of a phase 3 study of sugemalimab plus chemotherapy vs placebo plus chemotherapy in treatment-naïve advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma

报告人：张小田（北京大学肿瘤医院）

时间：17:20 - 17:25

03

摘要号：LBA80

标题：Tislelizumab (TIS) Plus Chemotherapy (Chemo) vs Placebo (PBO) Plus Chemo as First-Line (1L) Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (GC/GEJC): Final Analysis Results of the RATIONALE-305 Study

报告人：徐瑞华（中山大学肿瘤防治中心）

时间：17:25 - 17:30

04

摘要号：LBA81

标题：Updated efficacy and safety results from phase 3 GLOW study evaluating zolbetuximab + CAPOX as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2−, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GE J) adenocarcinoma

报告人：Florian Lordick（Leipzig, Germany）

时间：17:50 - 17:55

05

摘要号：LBA82

标题：Updated efficacy and safety results from phase 3 SPOTLIGHT study evaluating zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2−, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma

报告人：Jaffer A. Ajani（Houston, United States of America）

时间：17:55 - 18:00

06

摘要号：95MO

标题：Tinengotinib in Patients with Advanced, Fibroblast Growth Factor Receptor (FGFR) inhibitor Refractory/Relapsed Cholangiocarcinoma

报告人：Meredith S. Pelster（Nashville, United States of America）

时间：16:40 - 16:45

07

摘要号：945MO

标题：AdvanTIG-206: Phase 2 Randomized Open-Label Study of Ociperlimab (OCI) + Tislelizumab (TIS) + BAT1706 (Bevacizumab Biosimilar) Versus TIS + BAT1706 in Patients (pts) With Advanced Hepatocellular Carcinoma (HCC)

报告人：Ming Mo Hou (桃园，中国台湾)

时间：16:30 - 16:35

08

摘要号：1512MO

标题：Perioperative camrelizumab (C) combined with rivoceranib (R) and chemotherapy (chemo) versus chemo for locally advanced resectable gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: the first interim analysis of a randomized, phase 3 trial (DRAGON IV)

报告人：陈立（上海交通大学医学院附属瑞金医院）

时间：17:00 - 17:05

09

摘要号：1513MO

标题：A Phase II study of Nivolumab plus low dose Ipilimumab as 1st line therapy in patients with advanced gastric or esophago-gastric junction MSI-H tumor: First results of the NO LIMIT study (WJOG13320G/CA209-7W7)

报告人：Kei Muro（Nagoya, Japan）

时间：17:30 - 17:35

口头报告 - 研究性免疫疗法

Proffered Paper session - Investigational immunotherapy  

日期：2023年10月23日，星期一

时间：10:15 - 11:40

主席：Gary Middleton (Birmingham, United Kingdom), Alessandra Curioni-Fontecedro (Villar sur Glane, Switzerland)

地点：Burgos Auditorium - Hall 3

01

摘要号：1818O

标题：Phase I Study of GCC CAR-T therapy IM96 in Patients With Advanced Colorectal Cancer

报告人：齐长松 (北京大学肿瘤医院)

时间：10:55 - 11:05

迷你口头报告 - 研究性免疫疗法

Mini oral session - Investigational immunotherapy

日期：2023年10月21日，星期六

时间：16:30 - 17:50

主席：Alessandra Curioni-Fontecedro (Villar sur Glane, Switzerland), María José De Miguel (Madrid, Spain)

地点：Málaga Auditorium - Hall 10

01

摘要号：1020MO

标题：AdvanTIG-203: Phase 2 Randomized, Multicenter Study of Ociperlimab (OCI) + Tislelizumab (TIS) in Patients (pts) With Unresectable, Locally Advanced, Recurrent/Metastatic Esophageal Squamous Cell Carcinoma (ESCC) and Programmed Cell Death-Ligand 1 (PD-L1) Positivity

报告人：王峰 (中山大学肿瘤防治中心)

时间：16:30 - 16:35

备注：排名不分先后，排序参照摘要号进行

如有遗漏或任何问题，请给我们留言~